source
- Jazz partners with AbCellera on $4 billion deal to develop next-generation T-cell engagers for solid tumorsJazz Pharmaceuticals disclosed a collaboration with AbCellera aimed at creating next-generation T-cell-engaging antibodies for solid tumors. Under the agreement Jazz will pay $56 million up front…
- Eli Lilly to acquire non-opioid pain drug developer 4E Therapeutics, adding MNK inhibitor pipelineEli Lilly announced it will purchase 4E Therapeutics, a biotech focused on non‑opioid pain treatments. The acquisition gives Lilly access to 4E’s experimental pipeline, including MNK inhibitors su…